Thomas A. Collet
Gründer bei Phrixus Pharmaceuticals, Inc.
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Bruce Edward Markham | M | - |
Phrixus Pharmaceuticals, Inc.
 Phrixus Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Phrixus Pharmaceuticals, Inc. develops Carmeseal for DMD and for acute decompensated heart failure. It is repurposing Poloxamer for heart failure for which the only cure is heart transplantation. The company was founded by Thomas A. Collet and Bruce Markham in 2006 and is headquartered in Ann Arbor, MI. | 18 Jahre |
| Leslie J. Browne | M | 74 |
Phrixus Pharmaceuticals, Inc.
Phrixus Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Phrixus Pharmaceuticals, Inc. develops Carmeseal for DMD and for acute decompensated heart failure. It is repurposing Poloxamer for heart failure for which the only cure is heart transplantation. The company was founded by Thomas A. Collet and Bruce Markham in 2006 and is headquartered in Ann Arbor, MI. | 16 Jahre |
| Joshua Korzenik | M | - |
Bilayer Therapeutics, Inc.
 Bilayer Therapeutics, Inc. BiotechnologyHealth Technology Bilayer Therapeutics, Inc. is an American company that develops drugs for chronic disorders. The company was founded in 2020. The CEO is Thomas A. Collet. | - |
| Robert Langer | M | 74 |
Bilayer Therapeutics, Inc.
Bilayer Therapeutics, Inc. BiotechnologyHealth Technology Bilayer Therapeutics, Inc. is an American company that develops drugs for chronic disorders. The company was founded in 2020. The CEO is Thomas A. Collet. | - |
| Gerald D. Brennan | M | 73 |
Phrixus Pharmaceuticals, Inc.
Phrixus Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Phrixus Pharmaceuticals, Inc. develops Carmeseal for DMD and for acute decompensated heart failure. It is repurposing Poloxamer for heart failure for which the only cure is heart transplantation. The company was founded by Thomas A. Collet and Bruce Markham in 2006 and is headquartered in Ann Arbor, MI. | - |
| James Symons | M | - |
Phrixus Pharmaceuticals, Inc.
Phrixus Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Phrixus Pharmaceuticals, Inc. develops Carmeseal for DMD and for acute decompensated heart failure. It is repurposing Poloxamer for heart failure for which the only cure is heart transplantation. The company was founded by Thomas A. Collet and Bruce Markham in 2006 and is headquartered in Ann Arbor, MI. | - |
| David Zhu | M | - |
Bilayer Therapeutics, Inc.
Bilayer Therapeutics, Inc. BiotechnologyHealth Technology Bilayer Therapeutics, Inc. is an American company that develops drugs for chronic disorders. The company was founded in 2020. The CEO is Thomas A. Collet. | - |
| Joseph Metzger | M | - |
Phrixus Pharmaceuticals, Inc.
Phrixus Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Phrixus Pharmaceuticals, Inc. develops Carmeseal for DMD and for acute decompensated heart failure. It is repurposing Poloxamer for heart failure for which the only cure is heart transplantation. The company was founded by Thomas A. Collet and Bruce Markham in 2006 and is headquartered in Ann Arbor, MI. | - |
| Carlo Giovanni | M | - |
Bilayer Therapeutics, Inc.
Bilayer Therapeutics, Inc. BiotechnologyHealth Technology Bilayer Therapeutics, Inc. is an American company that develops drugs for chronic disorders. The company was founded in 2020. The CEO is Thomas A. Collet. | - |
| Yen Chen Huang | M | - |
Bilayer Therapeutics, Inc.
Bilayer Therapeutics, Inc. BiotechnologyHealth Technology Bilayer Therapeutics, Inc. is an American company that develops drugs for chronic disorders. The company was founded in 2020. The CEO is Thomas A. Collet. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 10 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Thomas A. Collet
- Persönliches Netzwerk
